03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
22:56 , Jun 25, 2018 |  BC Extra  |  Company News

CHMP interactions delaying Coherus biosimilar timeline

Coherus Biosciences Inc. (NASDAQ:CHRS) lost $1.80 (10%) to $15.40 on Monday after it disclosed that EMA's CHMP will require further interactions with the company in order to issue an opinion on its pending MAA for...
18:20 , May 25, 2018 |  BC Week In Review  |  Financial News

Coherus raises $75M in follow-on

Coherus BioSciences Inc. (NASDAQ:CHRS) raised $75 million late on May 22 through the sale of 5.2 million shares at $14.50 in a follow-on underwritten by J.P. Morgan, Citigroup, Mizuho, Baird, Maxim Group and H.C. Wainwright. The...
19:55 , May 23, 2018 |  BC Extra  |  Financial News

Coherus raises $75M in follow-on

Coherus BioSciences Inc. (NASDAQ:CHRS) raised $75 million through the sale of 5.2 million shares at $14.50 in a follow-on underwritten by J.P. Morgan, Citigroup, Mizuho, Baird, Maxim Group and H.C. Wainwright. The price is a 5%...
19:41 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA accepts resubmitted Coherus biosimilar BLA for review

Coherus BioSciences Inc. (NASDAQ:CHRS) said FDA accepted for review a resubmitted BLA for CHS-1701, a proposed biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). Its BSUFA date is Nov. 3. FDA issued a complete...
19:08 , May 4, 2018 |  BC Week In Review  |  Clinical News

Coherus resubmits BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) resubmitted a BLA for CHS-1701, its biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). FDA issued a complete response letter for the biosimilar last year, and Coherus said Thursday...
21:34 , May 3, 2018 |  BC Extra  |  Company News

Coherus resubmits BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) gained $2.20 (17%) to $14.90 on Thursday after resubmitting a BLA for CHS-1701, its biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). FDA issued a complete response letter for...
17:08 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Coherus plans to resubmit BLA for Neulasta biosimilar

In its FY17 earnings, Coherus BioSciences Inc. (NASDAQ:CHRS) said it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half. The company, which in November had said it...
23:44 , Mar 9, 2018 |  BC Extra  |  Company News

Coherus gains on plans to resubmit BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) rose $2.75 (30%) to $11.85 on Friday after announcing in its earnings that it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half....
01:38 , Jan 3, 2018 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury the...